Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advisory Committee Will Review ESAs In The Renal Setting Oct. 18

This article was originally published in The Pink Sheet Daily

Executive Summary

Meeting also could be next step in the process of determining whether safety issues are enough to drive changes to erythropoiesis-stimulating agent reimbursement at CMS.
Advertisement

Related Content

Can Amgen Stop The Bleeding As FDA Presses For A Low-Dose Aranesp Trial?
Can Amgen Stop The Bleeding As FDA Presses For A Low-Dose Aranesp Trial?
San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure
CMS Delays Inclusion Of Oral-Only ESRD Drugs In Final Bundled Payment Rule For Medicare
MedCAC Review Of ESAs In Renal Disease To Help Determine Need For NCD
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
Committee Rejects FDA’s Proposed Treatment Target For ESAs
Committee Rejects FDA’s Proposed Treatment Target For ESAs
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach

Topics

Advertisement
UsernamePublicRestriction

Register

PS071200

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel